Suggested remit: To appraise the clinical and cost effectiveness of emicizumab within its marketing authorisation for preventing bleeding episodes in people with mild or moderate haemophilia A without inhibitors.
Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
Further information The chair of TSOP has confirmed that it would not be an efficient use of NHS resources to conduct an evaluation at this time. Because emicizumab is covered by an existing NHS England clinical commissioning policy, NHS England have confirmed that this indication may be considered for routine commissioning.
ID number 5098

Project Team

Project lead Abigail Stephens

Email enquiries


Key events during the development of the guidance:

Date Update
16 February 2023 Topic selection. Changed back to TS to reflect TSOP not selected decision
16 February 2023 Topic selection
04 November 2022 - 02 December 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 July 2022 In progress. DHSC referral received
05 May 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on how we select topics for development, please see our page about topic selection